The COVID-19 Pandemic and its Impact on the Cardio-Oncology Population
- 28 May 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Current Oncology Reports
- Vol. 22 (6), 60
- https://doi.org/10.1007/s11912-020-00945-4
Abstract
Purpose of ReviewThe novel Coronavirus (2019-nCoV, COVID-19) is historically one of the most severe acute respiratory syndromes and pandemics to affect the globe in the twenty-first century. Originating in Wuhan, the virus rapidly spread and impacted subsets of populations with initial unclear risk factors contributing to worsening morbidity and mortality. Patients with diagnosis of cancer and undergoing treatment further represent a population at risk for worsening cardiopulmonary outcomes. This review explores specific risk factors, diagnoses, and treatment options that impact cardio-oncologic patients with COVID-19.Recent FindingsMultiple studies globally, including Italy, China, and the USA, have documented severe outcomes. Cancer patients are at increased risk of cardiac injury which itself is a risk factor for mortality. Additionally, elderly cancer patients undergoing recent anti-cancer treatment may be at greater risk for sustaining worse outcomes, although data remains suboptimal in this population. Major gaps remain regarding risk associated with type of cancer and type of anti-cancer treatment, as well as the layered risk of cardiovascular disease and cancer. Immunomodulatory therapies used to treat cytokine release syndrome secondary to anti-cancer therapies, as well as other agents being traditionally used to treat cardiovascular and cancer disease states, are being investigated for treatment of COVID-19.SummaryHypertension, cardiovascular disease, diabetes, and cancer have been associated with more severe COVID-19 infection and worse outcomes. Patients undergoing anti-cancer therapy or those who have suffered from coronavirus infection may develop long-standing changes, not limited to pulmonary fibrosis, hyperlipidemia, and worsening atherosclerosis. Those undergoing anti-cancer therapy are at theoretically increased susceptibility for infection, with type of cancer not necessarily dictating outcome. A review of the literature of patients with cardiovascular and/or cancer disease is presented, as well as proposed strategies to attenuate risk regarding treatment, management, and surveillance in this vulnerable population.Keywords
This publication has 104 references indexed in Scilit:
- Azithromycin and the Risk of Cardiovascular DeathThe New England Journal of Medicine, 2012
- Role of Tissue Factor in CancerJournal of Clinical Oncology, 2009
- Simvastatin Decreases Lipopolysaccharide-induced Pulmonary Inflammation in Healthy VolunteersAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Coronaviruses post-SARS: update on replication and pathogenesisNature Reviews Microbiology, 2009
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinThe New England Journal of Medicine, 2008
- Intubation of SARS patients: infection and perspectives of healthcare workersCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 2006
- Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2Journal of the American College of Cardiology, 2005
- ACE2: from vasopeptidase to SARS virus receptorTrends in Pharmacological Sciences, 2004
- Illness in Intensive Care Staff after Brief Exposure to Severe Acute Respiratory SyndromeEmerging Infectious Diseases, 2003
- Influence of hydroxychloroquine on the bioavailability of oral metoprololBritish Journal of Clinical Pharmacology, 2000